OBP is an animal vaccine-manufacturing company, whose mandate is to prevent and control animal diseases that affect food security, human health and livelihood. Inside sources allege it has been facing financial problems for years.
However, in response to the article carried on Wednesday (online) and yesterday (print), Lindiwe Mabena from the entity clarified that OBP received a R492 million allocation in 2013 to upgrade its Good Manufacturing Process (GMP) facility in order to be able to produce vaccines of global standard.
On the issue of the allegations of a mass staff exodus that has seen the chief financial officer, head of human resources and the head of legal affairs leaving and not being replaced, Mabena confirmed this, but said it did not hamper their work.
“These positions have little to no impact on the GMP project. The CFO and the head of HR resigned while on precautionary suspension and the head of legal resigned while on special leave.